NO20012303D0 - Farmasöytisk sammensetning for modifisert frigjöring av et insulinsensibiliserende middel og et annet antidiabetisk middel - Google Patents

Farmasöytisk sammensetning for modifisert frigjöring av et insulinsensibiliserende middel og et annet antidiabetisk middel

Info

Publication number: NO20012303D0
Authority: NO; Norway
Prior art keywords: agent; pharmaceutical composition; modified release; another anti; insulin sensitizing
Prior art date: 1998-11-12

Application number

NO20012303A

Other languages

English (en)

Other versions

NO20012303L (no

Inventor

Karen Lewis

Nicola Jayne Lilliot

Donald Colin Mackenzie

Vincenzo Re

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-11-12

Filing date

2001-05-10

Publication date

2001-05-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27547326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20012303(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-11-12 Priority claimed from GBGB9824869.3A external-priority patent/GB9824869D0/en

1998-11-12 Priority claimed from GBGB9824867.7A external-priority patent/GB9824867D0/en

1998-11-12 Priority claimed from GBGB9824866.9A external-priority patent/GB9824866D0/en

1999-05-25 Priority claimed from GBGB9912193.1A external-priority patent/GB9912193D0/en

1999-05-25 Priority claimed from GBGB9912190.7A external-priority patent/GB9912190D0/en

1999-05-25 Priority claimed from GBGB9912191.5A external-priority patent/GB9912191D0/en

2001-05-10 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2001-05-10 Publication of NO20012303D0 publication Critical patent/NO20012303D0/no

2001-07-04 Publication of NO20012303L publication Critical patent/NO20012303L/no

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
102000004877 Insulin Human genes 0.000 title 1
108090001061 Insulin Proteins 0.000 title 1
239000003472 antidiabetic agent Substances 0.000 title 1
229940125708 antidiabetic agent Drugs 0.000 title 1
239000003795 chemical substances by application Substances 0.000 title 1
229940125396 insulin Drugs 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
230000001235 sensitizing effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

NO20012303A 1998-11-12 2001-05-10 Farmasoytisk sammensetning for modifisert frigjoring av et insulinsensibiliserende middel og et annet antidiabetisk middel NO20012303L (no)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
GBGB9824869.3A GB9824869D0 (en)	1998-11-12	1998-11-12	Novel composition and use
GBGB9824867.7A GB9824867D0 (en)	1998-11-12	1998-11-12	Novel composition and use
GBGB9824866.9A GB9824866D0 (en)	1998-11-12	1998-11-12	Novel composition and use
GBGB9912193.1A GB9912193D0 (en)	1999-05-25	1999-05-25	Novel composition and use
GBGB9912190.7A GB9912190D0 (en)	1999-05-25	1999-05-25	Novel composition and use
GBGB9912191.5A GB9912191D0 (en)	1999-05-25	1999-05-25	Novel composition and use
PCT/EP1999/008704 WO2000028989A1 (en)	1998-11-12	1999-11-08	Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent

Publications (2)

Publication Number	Publication Date
NO20012303D0 true NO20012303D0 (no)	2001-05-10
NO20012303L NO20012303L (no)	2001-07-04

Family

ID=27547326

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20012303A NO20012303L (no)	1998-11-12	2001-05-10	Farmasoytisk sammensetning for modifisert frigjoring av et insulinsensibiliserende middel og et annet antidiabetisk middel

Country Status (36)

Country	Link
EP (3)	EP1813273A1 (no)
JP (1)	JP2002529504A (no)
KR (1)	KR100643833B1 (no)
CN (1)	CN1230162C (no)
AR (1)	AR024228A1 (no)
AT (1)	ATE406889T1 (no)
AU (1)	AU768994B2 (no)
BG (2)	BG109852A (no)
BR (1)	BR9915285A (no)
CA (1)	CA2351058A1 (no)
CY (1)	CY1108587T1 (no)
CZ (1)	CZ20011629A3 (no)
DE (1)	DE69939485D1 (no)
DK (1)	DK1131070T3 (no)
DZ (1)	DZ2936A1 (no)
EA (2)	EA007610B1 (no)
ES (1)	ES2312221T3 (no)
HK (1)	HK1040910B (no)
HR (1)	HRP20010343B1 (no)
HU (1)	HUP0104303A3 (no)
ID (1)	ID28783A (no)
IL (2)	IL143002A0 (no)
MY (1)	MY124695A (no)
NO (1)	NO20012303L (no)
NZ (1)	NZ511614A (no)
OA (1)	OA11677A (no)
PE (1)	PE20001238A1 (no)
PL (1)	PL347634A1 (no)
PT (1)	PT1131070E (no)
SI (1)	SI1131070T1 (no)
SK (1)	SK287038B6 (no)
TR (1)	TR200101333T2 (no)
TW (2)	TW592694B (no)
UY (1)	UY25799A1 (no)
WO (1)	WO2000028989A1 (no)
YU (1)	YU37301A (no)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6099862A (en) *	1998-08-31	2000-08-08	Andrx Corporation	Oral dosage form for the controlled release of a biguanide and sulfonylurea
AR030920A1 (es)	1999-11-16	2003-09-03	Smithkline Beecham Plc	Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
AU2007201729B2 (en) *	1999-12-23	2010-02-25	Novartis Ag	Use of hypoglycemic agent for treating impaired glucose metabolism
NZ531929A (en) *	1999-12-23	2006-01-27	Novartis Ag	Use of nateglinide as a hypoglycemic agent for treating impaired glucose metabolism
US6761901B1 (en)	2000-05-02	2004-07-13	Enzrel Inc.	Liposome drug delivery
FR2811227A1 (fr) *	2000-07-07	2002-01-11	Philippe Maincent	Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs
US8257744B2 (en) *	2000-07-07	2012-09-04	Laboratorios Farmacéuticos Rovi, S.A.	Pharmaceutical forms for the release of active compounds
US6866866B1 (en) *	2000-11-03	2005-03-15	Andrx Labs, Llc	Controlled release metformin compositions
US6790459B1 (en)	2000-11-03	2004-09-14	Andrx Labs, Llc	Methods for treating diabetes via administration of controlled release metformin
WO2002036100A1 (en) *	2000-11-03	2002-05-10	Andrx Corporation	Controlled release metformin compositions
FR2816840B1 (fr) *	2000-11-17	2004-04-09	Flamel Tech Sa	Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
BRPI0206432A2 (pt)	2001-01-12	2016-10-25	Sun Pharmaceutical Ind Ltd	métodos para administrar dois ou mais agentes terapêuticos ativos e para tratar diabetes melito ou sintomas associados com diabetes melito em um humano e sistema de liberação espaçada de medicamento
EP1372614A4 (en) *	2001-03-16	2007-10-31	Andrx Pharmaceuticals Llc	SULPHONYL UREA FORMULATION WITH CONTROLLED RELEASE
FR2822069B1 (fr) *	2001-03-19	2003-06-20	Lipha	Composition pharmaceutique comprenant un compose stimulant la secretion d'insuline et un derive de thiazolidinedione et son utilisation pour la preparation de medicamments destines a traiter le diabete
EP1392250A2 (en) *	2001-06-08	2004-03-03	Endo Pharmaceuticals Inc.	Controlled release dosage forms using acrylic polymer, and process for making the same
CA2453782A1 (en) *	2001-07-10	2003-01-23	Kos Life Sciences, Inc.	Core formulation comprising troglitazone and a biguanide
GB0127805D0 (en) *	2001-11-20	2002-01-09	Smithkline Beecham Plc	Pharmaceutical composition
US7183321B2 (en)	2001-12-17	2007-02-27	Bristol-Myers Squibb Company	Antidiabetic formulation and method
US6824790B2 (en)	2002-01-09	2004-11-30	Enzrel Inc.	Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
PE20030800A1 (es) *	2002-02-12	2003-10-31	Glaxo Group Ltd	Forma de dosificacion oral de liberacion controlada
JP4732696B2 (ja)	2002-04-09	2011-07-27	フラメル・テクノロジー	活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
EP1515701B1 (en) *	2002-06-17	2014-09-17	Inventia Healthcare Private Limited	Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
US7959946B2 (en)	2002-09-20	2011-06-14	Watson Pharmaceuticals, Inc.	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en)	2002-09-20	2015-06-23	Actavis, Inc.	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en)	2002-09-20	2011-12-27	Watson Pharmaceuticals, Inc.	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en)	2002-09-20	2010-08-31	Watson Pharmaceuticals, Inc.	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
UA80991C2 (en)	2002-10-07	2007-11-26		Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
EP1589951B1 (en) *	2003-01-03	2017-08-09	Supernus Pharmaceuticals, Inc.	Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics
WO2004067001A1 (ja)	2003-01-29	2004-08-12	Takeda Pharmaceutical Company Limited	被覆製剤の製造法
AR045330A1 (es) *	2003-08-07	2005-10-26	Sb Pharmco Inc	Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla
GB0318824D0 (en) *	2003-08-11	2003-09-10	Glaxo Group Ltd	Novel composition
GB0320522D0 (en)	2003-09-02	2003-10-01	Glaxo Group Ltd	Formulation
US7700128B2 (en)	2003-10-31	2010-04-20	Takeda Pharmaceutical Company Limited	Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
US8263121B2 (en)	2004-04-14	2012-09-11	Takeda Pharmaceutical Company Limited	Solid pharmaceutical preparation
WO2005105109A1 (en) *	2004-04-29	2005-11-10	Lotus Pharmaceutical Co., Ltd.	Oral modified-release lozenges and their preparation method
CN1327840C (zh) *	2004-06-08	2007-07-25	天津药物研究院	一种药物组合物及其在制备用于治疗糖尿病中的应用
GB0502475D0 (en) *	2005-02-07	2005-03-16	Sb Pharmco Inc	Novel compositions
KR100657785B1 (ko) *	2005-02-19	2007-04-16	한국유나이티드제약 주식회사	글리메피리드, 메트포르민 및 은행엽엑스를 함유하는 약학적 조성물
US20060222709A1 (en) *	2005-03-18	2006-10-05	Agi Therapeutics Research Ltd.	Metformin methods and formulations for treating chronic constipation
MXPA05010977A (es) *	2005-10-12	2007-04-11	Abdala Leopoldo Espinosa	Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus.
MXPA05014092A (es) *	2005-12-20	2007-06-20	Leopoldo De Jesus Espinosa Abdala	Composiciones farmaceuticas que comprenden sustancias derivadas de la tiazolidinedionas combinadas con una biguanida para su uso en diabetes mellitus tipo 2.
JP5179363B2 (ja) *	2005-12-22	2013-04-10	武田薬品工業株式会社	固形製剤
WO2008026668A1 (en) *	2006-08-31	2008-03-06	Daiichi Sankyo Company, Limited	Medicinal composition containing insulin resistance improving agent
KR100812538B1 (ko) *	2006-10-23	2008-03-11	한올제약주식회사	약물 제어방출형 메트포르민-글리메피리드 복합제제
EP2428204A3 (en) *	2006-12-07	2012-07-04	Schering Corporation	pH sensitive matrix formulation
ES2350029T3 (es) *	2007-03-02	2011-01-17	Farnam Companies, Inc.	Pellets de liberación sostenida que comprenden un material tipo cera.
WO2009017383A2 (en) *	2007-08-02	2009-02-05	Handok Pharmaceuticals Co., Ltd.	Sustained-release formulation comprising metformin acid salt
CN101801371B (zh)	2007-09-10	2012-11-28	詹森药业有限公司	可用作sglt抑制剂的化合物的制备方法
US8802156B2 (en)	2007-11-14	2014-08-12	Laboratorios Farmacéuticos Rovi, S.A.	Pharmaceutical forms for the release of active compounds
CN101548961B (zh) *	2008-04-03	2011-05-04	单宝华	一种治疗糖尿病及肥胖症的口服胶囊制剂
WO2010026467A2 (en) *	2008-09-04	2010-03-11	Torrent Pharmaceuticals Ltd.	Controlled release dosage form of high solubility active ingredient
US9056850B2 (en)	2008-10-17	2015-06-16	Janssen Pharmaceutica N.V.	Process for the preparation of compounds useful as inhibitors of SGLT
KR101189639B1 (ko) *	2008-12-15	2012-10-12	씨제이제일제당 (주)	메트포르민 및 α-글리코시다제 억제제를 포함하는 경구 제제 및 그 제조방법
US20110009347A1 (en)	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
RS55909B1 (sr)	2009-10-14	2017-09-29	Janssen Pharmaceutica Nv	Proces za pripremu jedinjenja koja su korisna kao inhibitori sglt2
NZ703128A (en)	2010-05-11	2016-04-29	Janssen Pharmaceutica Nv	Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
AU2011276332A1 (en) *	2010-07-06	2013-01-17	Janssen Pharmaceutica Nv	Formulation for co-therapy treatment of diabetes
US11974971B2 (en)	2011-01-07	2024-05-07	Anji Pharmaceuticals Inc.	Compositions and methods for treating metabolic disorders
US9211263B2 (en)	2012-01-06	2015-12-15	Elcelyx Therapeutics, Inc.	Compositions and methods of treating metabolic disorders
US11759441B2 (en)	2011-01-07	2023-09-19	Anji Pharmaceuticals Inc.	Biguanide compositions and methods of treating metabolic disorders
SI2661266T1 (sl) *	2011-01-07	2021-01-29	Anji Pharma (Us) Llc	Terapije, na osnovi kemosenzoričnih receptorskih ligandov
US8796338B2 (en)	2011-01-07	2014-08-05	Elcelyx Therapeutics, Inc	Biguanide compositions and methods of treating metabolic disorders
US9480663B2 (en)	2011-01-07	2016-11-01	Elcelyx Therapeutics, Inc.	Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en)	2011-01-07	2017-02-21	Elcelyx Therapeutics, Inc.	Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
EP2697218B1 (en)	2011-04-13	2016-05-25	Janssen Pharmaceutica NV	Process for the preparation of compounds useful as inhibitors of sglt2
US9035044B2 (en)	2011-05-09	2015-05-19	Janssen Pharmaceutica Nv	L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
BR112014016810A8 (pt) *	2012-01-06	2017-07-04	Elcelyx Therapeutics Inc	composições e métodos para tratamento de distúrbios metabólicos
MX2014008190A (es) *	2012-01-06	2015-02-04	Elcelyx Therapeutics Inc	Composiciones de biguanida y métodos para tratar transtornos metabólicos.
CN102631332A (zh) *	2012-04-28	2012-08-15	邹立兴	一种伏格列波糖片剂及其制备方法
KR101409330B1 (ko) *	2012-05-11	2014-06-18	안국약품 주식회사	복용순응도가 향상된 서방성 당뇨병 치료용 복합제제 및 이의 제조방법
EP2958548A1 (en) *	2013-02-19	2015-12-30	Sanovel Ilac Sanayi ve Ticaret A.S.	A production process for gliclazide formulations
EP3943076A3 (en) *	2014-12-17	2022-04-13	Empros Pharma AB	A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
US20170071970A1 (en)	2015-09-15	2017-03-16	Janssen Pharmaceutica Nv	Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN105963280B (zh) *	2016-06-30	2018-11-06	合肥华方医药科技有限公司	一种伏格列波糖口腔速溶膜及其制备方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5522636A (en)	1978-08-04	1980-02-18	Takeda Chem Ind Ltd	Thiazoliding derivative
JPS5697277A (en)	1980-01-07	1981-08-05	Takeda Chem Ind Ltd	Thiazolidine derivative
US4538469A (en) *	1983-07-29	1985-09-03	Panametrics, Inc.	Integrated threshold arming method and apparatus
JPS6051189A (ja)	1983-08-30	1985-03-22	Sankyo Co Ltd	チアゾリジン誘導体およびその製造法
US4582839A (en)	1984-03-21	1986-04-15	Takeda Chemical Industries, Ltd.	2,4-thiazolidinediones
CN1003445B (zh)	1984-10-03	1989-03-01	武田药品工业株式会社	噻唑烷二酮衍生物，其制备方法和用途
DK173350B1 (da)	1985-02-26	2000-08-07	Sankyo Co	Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
JPH06779B2 (ja)	1985-06-10	1994-01-05	武田薬品工業株式会社	チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en)	1986-07-24	1989-03-14	Takeda Chemical Industries, Ltd.	Method for producing thiazolidinedione derivatives
EP0306228B1 (en)	1987-09-04	1999-11-17	Beecham Group Plc	Substituted thiazolidinedione derivatives
US4791125A (en)	1987-12-02	1988-12-13	Pfizer Inc.	Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
WO1989008650A1 (en)	1988-03-08	1989-09-21	Pfizer Inc.	Thiazolidinedione hypoglycemic agents
WO1989008651A1 (en)	1988-03-08	1989-09-21	Pfizer Inc.	Hypoglycemic thiazolidinedione derivatives
IL91398A (en) *	1988-08-30	1994-05-30	Pfizer	Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane
WO1991007107A1 (en)	1989-11-13	1991-05-30	Pfizer Inc.	Oxazolidinedione hypoglycemic agents
JP2630016B2 (ja) *	1990-05-21	1997-07-16	ヤマハ株式会社	吹奏感付加器を有する電子管楽器
US5089514A (en)	1990-06-14	1992-02-18	Pfizer Inc.	3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
EP0533933A4 (en)	1990-07-03	1993-05-05	Yamanouchi Pharmaceutical Co. Ltd.	Bisheterocyclic compound
EP0544696B1 (en)	1990-08-23	1995-01-11	Pfizer Inc.	Hypoglycemic hydroxyurea derivatives
JPH04210683A (ja)	1990-12-06	1992-07-31	Terumo Corp	チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5145684A (en) *	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
EP0579733B1 (en)	1991-04-11	2001-06-20	PHARMACIA & UPJOHN COMPANY	Thiazolidinedione derivatives, production and use thereof
US5183823A (en)	1991-04-11	1993-02-02	Takeda Chemical Industries, Ltd.	Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
US5502078A (en) *	1991-05-28	1996-03-26	Zeneca Limited	Chemical compounds
TW222626B (no)	1991-07-22	1994-04-21	Pfizer
FR2680512B1 (fr)	1991-08-20	1995-01-20	Adir	Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH05271204A (ja)	1992-03-26	1993-10-19	Japan Tobacco Inc	新規なトリアジン誘導体
US5264451A (en)	1992-04-07	1993-11-23	American Home Products Corporation	Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
AU3959193A (en)	1992-04-10	1993-11-18	Smithkline Beecham Plc	Heterocyclic compounds and their use in the treatment of type II-diabetes
WO1993022445A1 (en)	1992-05-05	1993-11-11	The Upjohn Company	A process for producing pioglitazone metabolite
KR950702545A (ko)	1992-07-03	1995-07-29	데이빗 로버츠	약제로서의 헤테로시클릭 화합물(Heterocyclic compounds as pharmaceutical)
US5232945A (en)	1992-07-20	1993-08-03	Pfizer Inc.	3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
GB9218830D0 (en)	1992-09-05	1992-10-21	Smithkline Beecham Plc	Novel compounds
RU2071783C1 (ru) *	1993-09-07	1997-01-20	Ессентукский центральный военный санаторий	Способ получения средства для лечения сахарного диабета
US5457109A (en)	1993-09-15	1995-10-10	Warner-Lambert Company	Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
DE4432757A1 (de) *	1994-09-14	1996-03-21	Boehringer Mannheim Gmbh	Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
TWI238064B (en) *	1995-06-20	2005-08-21	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
GB9619757D0 (en) *	1996-09-21	1996-11-06	Knoll Ag	Chemical process
RU2114617C1 (ru) *	1996-09-27	1998-07-10	Юрий Георгиевич Каминский	Антидиабетическое средство на основе янтарной кислоты
CN1256630A (zh) *	1997-03-24	2000-06-14	盖尔德马研究及发展公司	用于治疗非胰岛素依赖型糖尿病的类维生素a相关分子
GB9715295D0 (en) *	1997-07-18	1997-09-24	Smithkline Beecham Plc	Novel method of treatment

1999
- 1999-11-08 SK SK644-2001A patent/SK287038B6/sk not_active IP Right Cessation
- 1999-11-08 PT PT99964483T patent/PT1131070E/pt unknown
- 1999-11-08 JP JP2000582036A patent/JP2002529504A/ja not_active Ceased
- 1999-11-08 SI SI9931017T patent/SI1131070T1/sl unknown
- 1999-11-08 AU AU30338/00A patent/AU768994B2/en not_active Ceased
- 1999-11-08 CA CA002351058A patent/CA2351058A1/en not_active Abandoned
- 1999-11-08 BR BR9915285-1A patent/BR9915285A/pt not_active Application Discontinuation
- 1999-11-08 PL PL99347634A patent/PL347634A1/xx not_active Application Discontinuation
- 1999-11-08 HK HK02101023.7A patent/HK1040910B/en not_active IP Right Cessation
- 1999-11-08 EA EA200100541A patent/EA007610B1/ru not_active IP Right Cessation
- 1999-11-08 WO PCT/EP1999/008704 patent/WO2000028989A1/en not_active Ceased
- 1999-11-08 KR KR1020017005967A patent/KR100643833B1/ko not_active Expired - Fee Related
- 1999-11-08 EA EA200601145A patent/EA011633B1/ru not_active IP Right Cessation
- 1999-11-08 HU HU0104303A patent/HUP0104303A3/hu unknown
- 1999-11-08 CZ CZ20011629A patent/CZ20011629A3/cs unknown
- 1999-11-08 IL IL14300299A patent/IL143002A0/xx unknown
- 1999-11-08 EP EP07105992A patent/EP1813273A1/en not_active Withdrawn
- 1999-11-08 DE DE69939485T patent/DE69939485D1/de not_active Expired - Lifetime
- 1999-11-08 ES ES99964483T patent/ES2312221T3/es not_active Expired - Lifetime
- 1999-11-08 NZ NZ511614A patent/NZ511614A/en not_active IP Right Cessation
- 1999-11-08 EP EP08163249A patent/EP1992337A1/en not_active Withdrawn
- 1999-11-08 OA OA1200100117A patent/OA11677A/en unknown
- 1999-11-08 CN CNB998154792A patent/CN1230162C/zh not_active Expired - Fee Related
- 1999-11-08 EP EP99964483A patent/EP1131070B1/en not_active Revoked
- 1999-11-08 TR TR2001/01333T patent/TR200101333T2/xx unknown
- 1999-11-08 ID IDW00200101045A patent/ID28783A/id unknown
- 1999-11-08 DK DK99964483T patent/DK1131070T3/da active
- 1999-11-08 YU YU37301A patent/YU37301A/sh unknown
- 1999-11-08 HR HR20010343A patent/HRP20010343B1/xx not_active IP Right Cessation
- 1999-11-08 AT AT99964483T patent/ATE406889T1/de active
- 1999-11-10 AR ARP990105697A patent/AR024228A1/es unknown
- 1999-11-10 DZ DZ990236A patent/DZ2936A1/xx active
- 1999-11-11 MY MYPI99004896A patent/MY124695A/en unknown
- 1999-11-12 PE PE1999001146A patent/PE20001238A1/es not_active Application Discontinuation
- 1999-11-12 UY UY25799A patent/UY25799A1/es not_active Application Discontinuation
- 1999-12-24 TW TW088122853A patent/TW592694B/zh not_active IP Right Cessation
- 1999-12-24 TW TW093109152A patent/TWI251487B/zh not_active IP Right Cessation
2001
- 2001-05-07 IL IL143002A patent/IL143002A/en not_active IP Right Cessation
- 2001-05-10 NO NO20012303A patent/NO20012303L/no not_active Application Discontinuation
- 2001-06-07 BG BG109852A patent/BG109852A/bg unknown
- 2001-06-07 BG BG105568A patent/BG65351B1/bg unknown
2008
- 2008-11-24 CY CY20081101346T patent/CY1108587T1/el unknown

Also Published As

Publication number	Publication date
ATE406889T1 (de)	2008-09-15
BG105568A (en)	2002-01-31
EA200601145A1 (ru)	2009-04-28
CN1230162C (zh)	2005-12-07
AR024228A1 (es)	2002-09-25
EP1813273A1 (en)	2007-08-01
NO20012303L (no)	2001-07-04
ES2312221T3 (es)	2009-02-16
HUP0104303A3 (en)	2003-12-29
EA011633B1 (ru)	2009-04-28
HRP20010343B1 (hr)	2010-11-30
TWI251487B (en)	2006-03-21
EA007610B1 (ru)	2006-12-29
ID28783A (id)	2001-07-05
UY25799A1 (es)	2000-12-29
EP1992337A1 (en)	2008-11-19
BG65351B1 (bg)	2008-03-31
SI1131070T1 (sl)	2008-12-31
AU3033800A (en)	2000-06-05
WO2000028989A1 (en)	2000-05-25
YU37301A (sh)	2005-06-10
SK6442001A3 (en)	2001-12-03
CY1108587T1 (el)	2014-04-09
AU768994B2 (en)	2004-01-15
DZ2936A1 (fr)	2004-03-15
HUP0104303A2 (hu)	2002-03-28
DK1131070T3 (da)	2008-11-17
PE20001238A1 (es)	2001-01-11
HK1040910A1 (en)	2002-06-28
CZ20011629A3 (cs)	2001-12-12
TW592694B (en)	2004-06-21
TW200418453A (en)	2004-10-01
HK1040910B (en)	2009-06-26
NZ511614A (en)	2003-12-19
EP1131070A1 (en)	2001-09-12
IL143002A0 (en)	2002-04-21
IL143002A (en)	2007-02-11
JP2002529504A (ja)	2002-09-10
HRP20010343A2 (en)	2002-06-30
BG109852A (bg)	2008-11-28
PL347634A1 (en)	2002-04-22
MY124695A (en)	2006-06-30
DE69939485D1 (de)	2008-10-16
KR100643833B1 (ko)	2006-11-10
PT1131070E (pt)	2008-11-19
EP1131070B1 (en)	2008-09-03
KR20010080419A (ko)	2001-08-22
SK287038B6 (sk)	2009-10-07
TR200101333T2 (tr)	2001-10-22
EA200100541A1 (ru)	2001-10-22
OA11677A (en)	2005-01-12
CN1348369A (zh)	2002-05-08
BR9915285A (pt)	2001-08-07
CA2351058A1 (en)	2000-05-25

Publication	Publication Date	Title
NO20012303D0 (no)	2001-05-10	Farmasöytisk sammensetning for modifisert frigjöring av et insulinsensibiliserende middel og et annet antidiabetisk middel
NO20010260D0 (no)	2001-01-16	Tarmbeskyttelsesbelagt farmasöytisk tablett og fremgangsmåte for fremstilling
NO20005879L (no)	2001-01-18	Tarm-beskyttelsesbelagt farmasöytisk blanding og fremgangsmåte for fremstilling
NO20004741L (no)	2000-11-22	Farmasöytiske blandinger for forlenget peptidfrigjöring og fremstillingsmetode
NO20006630D0 (no)	2000-12-22	Farmasöytisk sammensetning for behandlingen av diabetes
NO20000932L (no)	2000-04-18	Farmasøytisk preparat for kombinasjon av piperidinoalkanol og dekongestant
PL352282A1 (en)	2003-08-11	Derivatives of thiazoles and pharmaceutical compositions containing these derivatives
IS1960B (is)	2004-11-15	Lyfjafræðileg blanda N-Píperídínó-3-pýrazólkarboxamíð afleiðum, söltum og lausnarsamböndum til munnlegrar inntöku
NO973479L (no)	1997-09-29	Substituerte heterosykliske forbindelser, fremgangsmåte for fremstilling og farmasöytiske blandinger inneholdende samme
NO20011950L (no)	2001-06-25	Farmasöytiske blandinger som inneholder poly(ADP-ribose) glukohydrolaseinhibitorer og fremgangsmåter for anvendelse avsamme
NO996266L (no)	1999-12-17	Behandling av diabetes tiazolidindion og metformin
NO20011695L (no)	2001-05-30	Farmasöytisk sammensetning med langvarig frigivelse og fremgangsmåte for å frigi farmasöytisk aktivt middel
NO20012351D0 (no)	2001-05-11	Farmasöytisk sammensetning for modifisert frigjöring av insulinsensibiliserende middel
NO20011157D0 (no)	2001-03-07	Benzenderivater og farmasøytisk anvendelse derav
DK0879824T3 (da)	2004-08-30	Triterpenderivater og middel mod leversygdom
NO983926L (no)	1999-03-01	Farmas°ytisk kombinasjonspreparat av en inhibitor av natrium-hydrogen-veksler og et legemiddel for behandling av hjertekretsl°p-sykdommer
PL361518A1 (pl)	2004-02-09	Zastosowanie substancji oraz kompozycja farmaceutyczna
DK0994706T3 (da)	2006-03-06	Præparater til oral indgivelse af taxaner og anvendelse deraf
NO983666D0 (no)	1998-08-11	Krystallmodifikasjon av et farmasöytisk middel
NO20021832L (no)	2000-01-04	Farmasöytiske sammensetninger av tizoksanid og nitazoksanid
PT1017388E (pt)	2003-12-31	Composicao farmaceutica contendo ibuprofeno e domperidona para o tratamento de enxaqueca
BR9806083A (pt)	1999-08-24	Composi-Æo farmac-utica para o tratamento da hapattite c
HUP0003634A3 (en)	2003-04-28	Use of thiazolidinedione and sulphonylurea derivatives for the preparation of pharmaceutical compositions treating diabetes
DE69907735D1 (de)	2003-06-12	Melatoninderivate und diese enthaltende pharmazeutische zubereitung
DE69725166D1 (de)	2003-10-30	Substituierte benzamidderivate und diese enthaltende pharmazeutische zusammensetzung

Legal Events

Date	Code	Title	Description
2011-01-17	FC2A	Withdrawal, rejection or dismissal of laid open patent application